ProKidney Corp.
Dominic Justewicz is a seasoned expert in the fields of bioanalytical development and molecular biology, with extensive experience spanning over two decades in the biotechnology and pharmaceutical industries. Currently serving as Senior Director at ProKidney Corp. since August 2022, Dominic previously held positions including Research Fellow at Allogene Therapeutics, where a data analysis paradigm was established for assessing product potency, and Associate Research Fellow at Pfizer, leading analytical development for allogeneic CAR T cell products. Prior roles also include Principal Scientist at Tengion, focusing on bioanalytical methods related to tissue engineering, and Senior Scientist at MedImmune Vaccines, where a comprehensive molecular biology program was developed to support vaccine manufacturing. Dominic holds a Ph.D. in Epidemiologic Sciences from the University of Michigan and has contributed to significant publications and presentations within the field.
This person is not in the org chart
This person is not in any teams
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.